Scientific references

References to Fetuin-A (AHSG) Human ELISA

• Blaha V, Mistrik E, Dusilova-Sulkova S, Kalousova M, Andrys C, Blaha M, Sobotka L. Circulating fetuin-A predicts early mortality in chronic hemodialysis patients. Clin Biochem. 2009 Jul;42 (10-11):996-1000
• Brettschneider J, Lehmensiek V, Mogel H, Pfeifle M, Dorst J, Hendrich C, Ludolph AC, Tumani H. Proteome analysis reveals candidate markers of disease progression in amyotrophic lateral sclerosis (ALS). Neurosci Lett. 2010 Jan 1;468 (1):23-7
• Briana DD, Boutsikou M, Gourgiotis D, Boutsikou T, Baka S, Marmarinos A, Hassiakos D, Malamitsi-Puchner A. Serum fetuin-A/alpha2-HS-glycoprotein in human pregnancies with normal and restricted fetal growth. J Matern Fetal Neonatal Med. 2008 Nov;21 (11):826-30
• Brix JM, Stingl H, Hollerl F, Schernthaner GH, Kopp HP, Schernthaner G. Elevated Fetuin-A concentrations in morbid obesity decrease after dramatic weight loss. J Clin Endocrinol Metab. 2010 Nov;95 (11):4877-81
• Caglar K, Yilmaz MI, Saglam M, Cakir E, Acikel C, Eyileten T, Yenicesu M, Oguz Y, Vural A, Carrero JJ, Axelsson J, Lindholm B, Stenvinkel P. Short-term treatment with sevelamer increases serum fetuin-a concentration and improves endothelial dysfunction in chronic kidney disease stage 4 patients. Clin J Am Soc Nephrol. 2008 Jan;3 (1):61-8
• Caglar K, Yilmaz MI, Saglam M, Cakir E, Kilic S, Sonmez A, Eyileten T, Yenicesu M, Oguz Y, Tasar M, Vural A, Ikizler TA, Stenvinkel P, Lindholm B. Serum fetuin-a concentration and endothelial dysfunction in chronic kidney disease. Nephron Clin Pract. 2008;108 (3):c233-40
• Cianciolo G, La Manna G, Donati G, Persici E, Dormi A, Cappuccilli ML, Corsini S, Fattori R, Russo V, Nastasi V, Coli L, Wratten M, Stefoni S. Coronary calcifications in end-stage renal disease patients: a new link between osteoprotegerin, diabetes and body mass index?. Blood Purif. 2010;29 (1):13-22
• Cutler P, Akuffo EL, Bodnar WM, Briggs DM, Davis JB, Debouck CM, Fox SM, Gibson RA, Gormley DA, Holbrook JD, Hunter AJ, Kinsey EE, Prinjha R, Richardson JC, Roses AD, Smith MA, Tsokanas N, Willé DR, Wu W, Yates JW, Gloger IS. Proteomic identification and early validation of complement 1 inhibitor and pigment epithelium-derived factor: Two novel biomarkers of Alzheimer's disease in human plasma. Proteomics. 7 Mar 2008;2 Issue 4:467 - 477
• Dervisoglu E, Kir HM, Kalender B, Caglayan C, Eraldemir C. Serum fetuin--a concentrations are inversely related to cytokine concentrations in patients with chronic renal failure. Cytokine. 2008 Dec;44 (3):323-7
• Eller P, Hochegger K, Feuchtner GM, Zitt E, Tancevski I, Ritsch A, Kronenberg F, Rosenkranz AR, Patsch JR, Mayer G. Impact of ENPP1 genotype on arterial calcification in patients with end-stage renal failure. Nephrol Dial Transplant. 2008 Jan;23 (1):321-7
• Emoto M, Mori K, Lee E, Kawano N, Yamazaki Y, Tsuchikura S, Morioka T, Koyama H, Shoji T, Inaba M, Nishizawa Y. Fetuin-A and atherosclerotic calcified plaque in patients with type 2 diabetes mellitus. Metabolism. 2010 Jun;59 (6):873-8
• Eraso LH, Ginwala N, Qasim AN, Mehta NN, Dlugash R, Kapoor S, Schwartz S, Schutta M, Iqbal N, Mohler ER 3rd, Reilly MP. Association of lower plasma fetuin-a levels with peripheral arterial disease in type 2 diabetes. Diabetes Care. 2010 Feb;33 (2):408-10
• Ford ML, Tomlinson LA, Smith ER, Rajkumar C, Holt SG. Fetuin-A is an independent determinant of change of aortic stiffness over 1 year in non-diabetic patients with CKD stages 3 and 4. Nephrol Dial Transplant. 2010 Jan 14;
• Hennige AM, Staiger H, Wicke C, Machicao F, Fritsche A, Haring HU, Stefan N. Fetuin-A induces cytokine expression and suppresses adiponectin production. PLoS One. 2008;3 (3):e1765
• Hussein NA, Mahmoud OM, Zahran MY, Rafaat MA. Serum Fetuin-A in Chronic Renal Disease Patients: Contribution to Endothelial Dysfunction and Hemostatic alteration. Journal of American Science. 2010;6(12);
• Kaden JJ, Reinohl JO, Blesch B, Brueckmann M, Haghi D, Borggrefe M, Schmitz F, Klomfass S, Pillich M, Ortlepp JR. Systemic and local levels of fetuin-A in calcific aortic valve stenosis. Int J Mol Med. 2007 Aug;20 (2):193-7
• Kamel AA, El-Attar HA, Abaza MM, Gaber EW, Badawi SS. Study of serum osteoprotegerin (OPG), tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and fetuin-A in patients with chronic renal failure. Bull. Alex. Fac. Med. 2007;43 (3)
• Katayama H, Paczesny S, Prentice R, Aragaki A, Faca VM, Pitteri SJ, Zhang Q, Wang H, Silva M, Kennedy J, Rossouw J, Jackson R, Hsia J, Chlebowski R, Manson J, Hanash S. Application of serum proteomics to the Women's Health Initiative conjugated equine estrogens trial reveals a multitude of effects relevant to clinical findings. Genome Med. 2009;1 (4):47
• Kaushik SV, Plaisance EP, Kim T, Huang EY, Mahurin AJ, Grandjean PW, Mathews ST. Extended-release niacin decreases serum fetuin-A concentrations in individuals with metabolic syndrome. Diabetes Metab Res Rev. 2009 Jul;25 (5):427-34
• Kloting N, Fasshauer M, Dietrich A, Kovacs P, Schon MR, Kern M, Stumvoll M, Bluher M. Insulin-sensitive obesity. Am J Physiol Endocrinol Metab. 2010 Sep;299 (3):E506-15
• Kusnierz-Cabala B, Gurda-Duda A, Panek J, Fedak D, Dumnicka P, Solnica B, Kulig J. Serum fetuin A concentrations in patients with acute pancreatitis. Clin Lab. 2010;56 (5-6):191-5
• Lorant DP, Grujicic M, Hoebaus C, Brix JM, Hoellerl F, Schernthaner G, Koppensteiner R, Schernthaner GH. Fetuin-A levels are increased in patients with type 2 diabetes and peripheral arterial disease. Diabetes Care. 2011 Jan;34 (1):156-61
• Mori K, Emoto M, Araki T, Yokoyama H, Teramura M, Lee E, Motoyama K, Koyama H, Shoji T, Inaba M, Nishizawa Y. Association of serum fetuin-A with carotid arterial stiffness. Clin Endocrinol (Oxf) . Feb;66(2):246-50 (2007)
• Mori K, Emoto M, Yokoyama H, Araki T, Teramura M, Koyama H, Shoji T, Inaba M, Nishizawa Y. Association of serum fetuin-A with insulin resistance in type 2 diabetic and nondiabetic subjects. Diabetes Care . Feb;29(2):468 (2006)
• Oikawa O, Higuchi T, Yamazaki T, Yamamoto C, Fukuda N, Matsumoto K. Evaluation of serum fetuin-A relationships with biochemical parameters in patients on hemodialysis. Clin Exp Nephrol. 2007 Dec;11 (4):304-8
• Panczyk-Tomaszewska M, Skrzypczyk P, Ziolkowska H, Adamczuk D, Roszkowska-Blaim M. [Fetuin A in children with nephrotic syndrome]. Pol Merkur Lekarski. 2008;24 Suppl 4:65-7
• Pertosa G, Simone S, Ciccone M, Porreca S, Zaza G, Dalfino G, Memoli B, Procino A, Bonomini M, Sirolli V, Castellano G, Gesualdo L, Ktena M, Schena FP, Grandaliano G. Serum fetuin a in hemodialysis: a link between derangement of calcium-phosphorus homeostasis and progression of atherosclerosis?. Am J Kidney Dis. 2009 Mar;53 (3):467-74
• Petrik V, Saadoun S, Loosemore A, Hobbs J, Opstad KS, Sheldon J, Tarelli E, Howe FA, Bell BA, Papadopoulos MC. Serum alpha 2-HS glycoprotein predicts survival in patients with glioblastoma. Clin Chem. 2008 Apr;54 (4):713-22
• Roos M, Richart T, Kouznetsova T, von Eynatten M, Lutz J, Heemann U, Baumann M, Staessen JA. Fetuin-A and arterial stiffness in patients with normal kidney function. Regul Pept. 2009 Apr 10;154 (1-3):39-43
• Sigrist MK, Levin A, Er L, McIntyre CW. Elevated osteoprotegerin is associated with all-cause mortality in CKD stage 4 and 5 patients in addition to vascular calcification. Nephrol Dial Transplant. 2009 Oct;24 (10):3157-62
• Sigrist MK, Taal MW, Bungay P, McIntyre CW. Progressive vascular calcification over 2 years is associated with arterial stiffening and increased mortality in patients with stages 4 and 5 chronic kidney disease. Clin J Am Soc Nephrol. 2007 Nov;2 (6):1241-8
• Smith ER, Ford ML, Tomlinson LA, Rocks BF, Rajkumar C, Holt SG. Poor agreement between commercial ELISAs for plasma fetuin-A: an effect of protein glycosylation?. Clin Chim Acta. 2010 Apr 25;
• Stefan N, Hennige AM, Staiger H, Machann J, Schick F, Krober SM, Machicao F, Fritsche A, Haring HU. Alpha2-Heremans-Schmid glycoprotein/fetuin-A is associated with insulin resistance and fat accumulation in the liver in humans. Diabetes Care . Apr;29(4):853-7 (2006)
• Stejskal D, Karpisek M, Vrtal R, Student V, Solichova P, Fiala R, Stejskal P. Urine fetuin-A values in relation to the presence of urolithiasis. BJU Int. 2008 May;101 (9):1151-4
• Tonjes A, Fasshauer M, Kratzsch J, Stumvoll M, Bluher M. Adipokine pattern in subjects with impaired fasting glucose and impaired glucose tolerance in comparison to normal glucose tolerance and diabetes. PLoS One. 2010;5 (11):e13911
• Tumani H, Lehmensiek V, Rau D, Guttmann I, Tauscher G, Mogel H, Palm C, Hirt V, Suessmuth SD, Sapunova-Meier I, Ludolph AC, Brettschneider J. CSF proteome analysis in clinically isolated syndrome (CIS): candidate markers for conversion to definite multiple sclerosis. Neurosci Lett. 2009 Mar 13;452 (2):214-7
• Urbanova M, Kalousova M, Zima T, Skibova J, Wohlfahrt P, Viklicky O. Fetuin-A early after renal transplantation. Kidney Blood Press Res. 2009;32 (3):217-22
• Uz O, Kardesoglu E, Yiginer O, Bas S, Ipcioglu OM, Ozmen N, Aparci M, Cingozbay BY, Isilak Z, Cebeci BS. The relationship between coronary calcification and the metabolic markers of osteopontin, fetuin-A, and visfatin. Turk Kardiyol Dern Ars. 2009 Sep;37 (6):397-402
• Wojtysiak-Duma B, Duma D, Burska A, Janicki K, Zakaszewska K, Skałecki P, Janicka L, Solski J. Fetuin-A in patients undergoing peritoneal dialysis with coronary artery calcification. Annales Universitatis Marie Cu. XXI, N 1, 68, 2008
• Yang SJ, Hong HC, Choi HY, Yoo HJ, Cho GJ, Hwang TG, Baik SH, Choi DS, Kim SM, Choi KM. Effects of a three-month combined exercise programme on fibroblast growth factor 21 and fetuin-A levels and arterial stiffness in obese women. Clin Endocrinol (Oxf). 2011 Oct;75 (4):464-9
• Yilmaz MI, Saglam M, Qureshi AR, Carrero JJ, Caglar K, Eyileten T, Sonmez A, Cakir E, Oguz Y, Vural A, Yenicesu M, Stenvinkel P, Lindholm B, Axelsson J. Endothelial dysfunction in type-2 diabetics with early diabetic nephropathy is associated with low circulating adiponectin. Nephrol Dial Transplant. 2008 May;23 (5):1621-7
• Ziolkowska H, Brzewski M, Roszkowska-Blaim M. Determinants of the intima-media thickness in children and adolescents with chronic kidney disease. Pediatr Nephrol. 2008 May;23 (5):805-11
• Ziolkowska H, Wojnar J, Panczyk-Tomaszewska M, Roszkowska-Blaim M. [Fetuin A in children with renal diseases]. Przegl Lek. 2006;63 Suppl 3:54-6

References to Fetuin-A (AHSG) Human, Goat Polyclonal Antibody

• Fisher E, Stefan N, Saar K, Drogan D, Schulze MB, Fritsche A, Joost HG, Haring HU, Hubner N, Boeing H, Weikert C. Association of AHSG gene polymorphisms with fetuin-A plasma levels and cardiovascular diseases in the EPIC-Potsdam study. Circ Cardiovasc Genet. 2009 Dec;2 (6):607-13
• Roos M, Lutz J, Salmhofer H, Luppa P, Knauss A, Braun S, Martinof S, Schomig A, Heemann U, Kastrati A, Hausleiter J. Relation between plasma fibroblast growth factor-23, serum fetuin-A levels and coronary artery calcification evaluated by multislice computed tomography in patients with normal kidney function. Clin Endocrinol (Oxf). 2008 Apr;68 (4):660-5
• Stefan N, Fritsche A, Weikert C, Boeing H, Joost HG, Haring HU, Schulze MB. Plasma Fetuin-A Levels and the Risk of Type 2 Diabetes. Diabetes. 2008 Jul 15;
• Weikert C, Stefan N, Schulze MB, Pischon T, Berger K, Joost HG, Haring HU, Boeing H, Fritsche A. Plasma Fetuin-A Levels and the Risk of Myocardial Infarction and Ischemic Stroke. Circulation. 2008 Nov 24;

References to Fetuin-A (AHSG) Human, Rabbit Polyclonal Antibody

• Ketteler M, Gross ML, Ritz E. Calcification and cardiovascular problems in renal failure. Kidney Int Suppl . Apr;(94):S120-7 (2005)

References to Fibroblast Growth Factor 19 Human ELISA

• Dostalova I, Kavalkova P, Haluzikova D, Lacinova Z, Mraz M, Papezova H, Haluzik M. Plasma concentrations of fibroblast growth factors 19 and 21 in patients with anorexia nervosa. J Clin Endocrinol Metab. 2008 Jun 17;